Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.57 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.52 |
| ▸ | GRM8 | O00222 | 4/20 | 0.52 |
| ▸ | GRM6 | O15303 | 3/20 | 0.52 |
| ▸ | ARG1 | P05089 | 5/20 | 0.38 |
| ▸ | ARG2 | P78540 | 4/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17188782 | 0.82 | GRM2 (0.37) | GRM2GRM1GRM5GRM4GRM8 | |
| SCHEMBL3372193 | 0.78 | GRM2 (0.34) | GRM2GRM1GRM5GRM4GRM8 | |
| SCHEMBL13757793 | 0.78 | GRM2 (0.34) | GRM2GRM1GRM5GRM4GRM8 | |
| SCHEMBL3196628 | 0.74 | — | — | |
| SCHEMBL3196640 | 0.74 | — | — | |
| SCHEMBL3294258 | 0.72 | — | — | |
| SCHEMBL594504 | 0.72 | — | — | |
| SCHEMBL14647435 | 0.72 | — | — | |
| SCHEMBL16535275 | 0.72 | GRM2 (1.00) | GRM2GRM1GRM5GRM4GRM8 | |
| SCHEMBL16240415 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273760-A1 | A TEIXOBACTIN ANALOGUE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-09-01 | — | — | US | disclosed |
| WO-2021013217-A1 | A TEIXOBACTIN ANALOGUE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273760-A1 | A TEIXOBACTIN ANALOGUE AND USE THEREOF | TALDO1, NAMPT, TES | GRM2 4848/4885GRM1 4543/4885GRM5 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.